BeiGene(BGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BGNE BeiGene

Trading 11-25 11:16:21 EST

189.60

-0.91

-0.48%

High194.98	Low189.52	Vol64.74K
Open192.03	D1 Closing190.51	Amplitude2.87%
Mkt Cap20.14B	Tradable Cap11.54B	Total Shares106.25M
T/O12.39M	T/O Rate0.11%	Tradable Shares60.89M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BGNE","market":"US","secType":"STK","nameCN":"BeiGene","latestPrice":189.6,"timestamp":1732551378885,"preClose":190.51,"halted":0,"volume":64737,"delay":0,"floatShares":60885100,"shares":106246194,"eps":-8.186614,"marketStatus":"Trading","change":-0.91,"latestTime":"11-25 11:16:21 EST","open":192.03,"high":194.98,"low":189.52,"amount":12385899.098909998,"amplitude":0.02866,"askPrice":189.95,"askSize":139,"bidPrice":189.52,"bidSize":59,"shortable":3,"etf":0,"ttmEps":-8.186614,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1732568400000},"marketStatusCode":2,"adr":1,"adrRate":13,"exchange":"NASDAQ","adjPreClose":190.51,"preHourTrading":{"tag":"盘前","latestPrice":194.04,"preClose":190.51,"latestTime":"08:39 EST","volume":3,"amount":582.12,"timestamp":1732541958281},"postHourTrading":{"tag":"盘后","latestPrice":190.51,"preClose":190.51,"latestTime":"17:20 EST","volume":4843,"amount":922648.05,"timestamp":1732314029188},"volumeRatio":0.801715,"impliedVol":0.391,"impliedVolPercentile":0.2421},"requestUrl":"/m/hq/s/BGNE","defaultTab":"news","newsList":[{"id":"2485963492","title":"Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK","url":"https://stock-news.laohu8.com/highlight/detail?id=2485963492","media":"Dow Jones","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485963492?lang=en_us&edition=fundamental","pubTime":"2024-11-21 22:30","pubTimestamp":1732199400,"startTime":"0","endTime":"0","summary":"Shares of Zymeworks rose early Thursday after the cancer therapy it is developing with Jazz Pharmaceuticals received accelerated regulatory approval for treating forms of biliary tract cancer.Zymeworks' stock was up 8.3% to $15.75 in pre-market trading. Shares are up about 40% this year as of Wednesday's close.The U.S. Food and Drug Administration granted Ziihera, an antibody treatment, accelerated approval for injection for intravenous use in treating adults with certain forms of biliary tract cancer.Zymeworks first developed the molecule, and in 2022 entered a license and collaboration deal with Jazz for exclusive development and commercialization rights to the compound in most countries. Under the licensing deal, Zymeworks has earned a milestone payment of $25 million based on FDA approval of Ziihera in BTC.Jazz shares were up about 2.3% in pre-market trading.BeiGene has the compound's license in Asia Pacific territories.Zymeworks said Ziihera was the first candidate in its pipeline","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","LU0109394709.USD","LU0320765992.SGD","ZYME","BGNE","BK4139","BK4007","BK4548","BK4532","BK4535","JAZZ","BK4505","BK4533","BK4526","LU0889565916.HKD","BK4504"],"gpt_icon":0},{"id":"2485714482","title":"China ADRs have increased to the largest share since late 2021 – GS","url":"https://stock-news.laohu8.com/highlight/detail?id=2485714482","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485714482?lang=en_us&edition=fundamental","pubTime":"2024-11-21 00:22","pubTimestamp":1732119750,"startTime":"0","endTime":"0","summary":"Leestat/iStock via Getty Images At the start of the fourth quarter, a quarter of U.S. hedge funds held a long position in at least one China ADR (American depositary receipt).  This is the highest sha","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1264992407/image_1264992407.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1264992407/image_1264992407.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4312555-china-adrs-have-increased-to-the-largest-share-since-late-2021-gs","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["01698","43A.SI","ATAT","LU0821914370.USD","BK4503","FXI","LU1048596156.SGD","LU1152091168.USD","IE00BGV7N243.SGD","PDD","BGNE","LU2476274308.USD","NIO.SI","ZLAB","ZTO","LU0310800965.SGD","BK4531","BK4501","LU0880133367.SGD","LU0320764599.SGD","LU2087589342.USD","LU0048580855.USD","LU0359201612.USD","QFIN","BK4588","LU0231483743.USD","HTHT","TME","RLX","EVS.SI","NIO","09618","LU0149534421.HKD","09866","TME.AU","LU0823426480.USD","09988","BK4122","BK4534","LU0348814723.USD","KWEB","LU0417516902.SGD","LI","LU1023057109.AUD","GDS","JD","LU0370786039.SGD","BABA","LU2778985437.USD"],"gpt_icon":1},{"id":"2484946591","title":"Labcorp Holdings Finance Chief Glenn Eisenberg to Retire","url":"https://stock-news.laohu8.com/highlight/detail?id=2484946591","media":"MT Newswires Live","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484946591?lang=en_us&edition=fundamental","pubTime":"2024-11-19 20:57","pubTimestamp":1732021064,"startTime":"0","endTime":"0","summary":"Labcorp Holdings  said Tuesday that Chief Financial Officer Glenn Eisenberg plans to retire on Dec. 2.Julia Wang, previously CFO of BeiGene , will take over Eisenberg's roles as CFO and executive vice president, Labcorp said.Eisenberg will remain as special adviser to the company through April 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4548","BK4585","BK4535","BK4588","BK4504","BK4550","LH","BGNE","BK4196","LU0006061336.USD","BK4505","BK4139","BK4526"],"gpt_icon":0},{"id":"2484946320","title":"Labcorp gets new finance chief","url":"https://stock-news.laohu8.com/highlight/detail?id=2484946320","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484946320?lang=en_us&edition=fundamental","pubTime":"2024-11-19 20:46","pubTimestamp":1732020409,"startTime":"0","endTime":"0","summary":"Labcorp  said that its executive VP and CFO Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as executive VP and CFO. Mr. Eisenberg will remain at Labcorp as special advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.  Most recently, Ms. Wang served as CFO of BeiGene .","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4306302-labcorp-gets-new-finance-chief","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BK4504","BK4585","BK4588","BK4535","BK4139","BK4526","BK4550","LH","BK4196","LU0006061336.USD","BK4548","BGNE","BK4505"],"gpt_icon":0},{"id":"2484485079","title":"BeiGene Announces U.S. Regulatory Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2484485079","media":"TIPRANKS","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484485079?lang=en_us&edition=fundamental","pubTime":"2024-11-19 20:09","pubTimestamp":1732018156,"startTime":"0","endTime":"0","summary":"BeiGene Ltd (HK:6160) has released an update. BeiGene, Ltd., a biotechnology company incorporated in the Cayman Islands, has announced a regulatory...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beigene-announces-u-s-regulatory-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beigene-announces-u-s-regulatory-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","BK4504","BK4505","BGNE","BK4526","BK4588","BK4535","BK4548"],"gpt_icon":0},{"id":"2484438129","title":"Labcorp CFO Glenn Eisenberg Announces Plans to Retire","url":"https://stock-news.laohu8.com/highlight/detail?id=2484438129","media":"PR Newswire","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484438129?lang=en_us&edition=fundamental","pubTime":"2024-11-19 20:00","pubTimestamp":1732017600,"startTime":"0","endTime":"0","summary":"Julia Wang Named Chief Financial Officer Beginning December 2, 2024. BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp , a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer  Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.\"I have long admired Labcorp as a trusted brand and am thrilled to join Labcorp as CFO and see clear opportunities to continue executing on our strategy to help deliver better outcomes for patients,\" said Ms. Wang. \"No doubt Labcorp offers a mission-driven, collaborative culture that delivers compelling value for patients, employees and shareholders. I look forward to workin","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XQveuHut.M3qb_14Vt_N2g--~B/aD0xMDc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/dfb2a169dcf74a375ce32bd7ba958549","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XQveuHut.M3qb_14Vt_N2g--~B/aD0xMDc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/dfb2a169dcf74a375ce32bd7ba958549"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/labcorp-cfo-glenn-eisenberg-announces-120000773.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/labcorp-cfo-glenn-eisenberg-announces-120000773.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4526","BK4588","BK4505","BK4196","CFO","GRO","BK4585","BGNE","BK4504","LH","LU0006061336.USD","BK4550","BK4548","BK4535","BK4139"],"gpt_icon":1},{"id":"2484991438","title":"BRIEF-BeiGene Announces Settlement Of Litigation Against Generic Filer Of BRUKINSA","url":"https://stock-news.laohu8.com/highlight/detail?id=2484991438","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484991438?lang=en_us&edition=fundamental","pubTime":"2024-11-19 19:11","pubTimestamp":1732014676,"startTime":"0","endTime":"0","summary":"Nov 19  - Beigene Ltd   :   * BEIGENE ANNOUNCES SETTLEMENT OF LITIGATION AGAINST GENERIC FILER OF BRUKINSA   * BEIGENE ANNOUNCES SETTLEMENT OF LITIGATION AGAINST GENERIC FILER OF BRUKINSA   * BEIGENE LTD: AGREEMENT PROVIDES FOR GENERIC ENTRY OF INNOVATIVE BTK INHIBITOR IN 2037Source text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BGNE","BK4585","BK4548","BK4504","BK4535","BK4526","BK4588","BK4139"],"gpt_icon":0},{"id":"2484914717","title":"BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA","url":"https://stock-news.laohu8.com/highlight/detail?id=2484914717","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484914717?lang=en_us&edition=fundamental","pubTime":"2024-11-19 19:00","pubTimestamp":1732014000,"startTime":"0","endTime":"0","summary":"Agreement provides for generic entry of innovative BTK inhibitor in 2037. SAN MATEO, Calif., November 19, 2024----BeiGene, Ltd. , a global oncology company which intends to change its name to BeOne Medicines Ltd., today announced it has entered into a settlement agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd. resolving patent litigation related to MSN’s Abbreviated New Drug Application  seeking approval to market a generic version of BRUKINSA  in the U.S.The settlement resolves all patent litigation brought by BeiGene against companies that sought to market generic versions of BRUKINSA. BeiGene and Sandoz Inc. previously filed a joint stipulation to dismiss patent litigation brought by BeiGene in response to Sandoz’s ANDA seeking approval to market a generic version of BRUKINSA.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0jbh5O0kYRbY8MNUE0gqQA--~B/aD0zMTA7dz0xNjUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cb4d8cf1634314593fc0a06866707f2f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0jbh5O0kYRbY8MNUE0gqQA--~B/aD0zMTA7dz0xNjUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cb4d8cf1634314593fc0a06866707f2f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-announces-settlement-litigation-against-110000601.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4585","BK4505","BK4526","BK4535","BK4504","BK4548","BK4588","BGNE"],"gpt_icon":1},{"id":"2484916912","title":"BeiGene Announces New Share Options and RSUs","url":"https://stock-news.laohu8.com/highlight/detail?id=2484916912","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484916912?lang=en_us&edition=fundamental","pubTime":"2024-11-19 18:12","pubTimestamp":1732011168,"startTime":"0","endTime":"0","summary":"BeiGene Ltd (HK:6160) has released an update. BeiGene Ltd has announced the grant of share options and restricted share units under its 2016 Share ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beigene-announces-new-share-options-and-rsus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beigene-announces-new-share-options-and-rsus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4588","BK4504","BK4535","BK4548","BK4585","BK4139","BK4526","BGNE"],"gpt_icon":0},{"id":"2483307138","title":"BeiGene, Ltd. (BGNE): Among 12 High Growth Large Cap Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2483307138","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483307138?lang=en_us&edition=fundamental","pubTime":"2024-11-16 01:20","pubTimestamp":1731691215,"startTime":"0","endTime":"0","summary":"We recently published a list of 12 High Growth Large Cap Stocks to Buy Now.In this article, we are going to take a look at where BeiGene, Ltd.  stands against other high growth large cap stocks.BlackRock highlighted that its portfolio managers are broadly optimistic about US equities. Its portfolio managers opine that there is still some expected upside potential, despite the steep US stock valuations. However, the contrast between lagging European economic growth, and stock performance, is stark. The US Fed decided to reduce the policy rate by another 25 bps in a recent meeting as the apex bank sees inflation moving closer to its target of 2%.However, the financial conditions remain loose after a historically sharp tightening cycle. The firm believes that such an unusual backdrop strengthens its view that the environment is being dominated by structural forces and not by a typical business cycle.Overall, the firm remains overweight on the US given the positive view on the AI theme. Th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Uuiz66r8r7FYOkcrCd745w--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/7aa5d9f1e458b266ca8df5556a95f97d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Uuiz66r8r7FYOkcrCd745w--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/7aa5d9f1e458b266ca8df5556a95f97d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-ltd-bgne-among-12-172015230.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4535","IE00BSNM7G36.USD","BK4533","LU2237443465.HKD","IE0002270589.USD","LU2237443895.HKD","LU2237443549.SGD","BK4139","BK4504","BK4585","BK4526","OEX","LU2237443622.USD","QID","BK4127","BK4516","IVV","LU2237443978.SGD","SPY","QLD","LU0106831901.USD","BK4534","PSQ","NQmain","IE0034235188.USD","IE0004086264.USD","OEF","ESmain","BK4588","SSO",".SPX","TQQQ","UPRO","BK4548","BK4559","BK4581","VOO","BGNE","SQQQ",".IXIC","BEIGF","MNQmain","BK4550","LU1668664300.SGD","SDS","SH","SPXU","LU2237438978.USD","IE00BFXG1179.USD"],"gpt_icon":1},{"id":"2483680930","title":"Sector Update: Health Care Stocks Advance Pre-Bell Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2483680930","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483680930?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:20","pubTimestamp":1731594029,"startTime":"0","endTime":"0","summary":"Health care stocks were advancing pre-bell Thursday as the iShares Biotechnology ETF (IBB) was marginally higher and the Health Care Select Sector SPDR Fund (XLV) was up 0.1% recently.ClearPoint Neuro","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","CLPT","BK4504","BK4535","LU0109394709.USD","BK4585","LU0320765992.SGD","BK4526","BK4505","BK4139","BK4082","BK4548","BK4581","BGNE","IBB","PTCT","LU0889565916.HKD","XLV"],"gpt_icon":0},{"id":"2483794568","title":"BeiGene Proposes Name Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2483794568","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483794568?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:15","pubTimestamp":1731586527,"startTime":"0","endTime":"0","summary":"BeiGene  is proposing to change its English name to BeOne Medicines, while keeping its Chinese name unchanged, a Thursday bourse filing said.The proposal comes about in order to reaffirm the drugmaker's commitment to develop innovative medicines to eliminate cancer by partnering with the global community and treat as many patients as possible.The name change is subject to shareholder and regulatory approvals.Hong Kong-listed shares of the company closed over 3% lower on Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1583","LU0307460666.USD","LU1969619763.USD","BK4588","BK1500","BK4548","BGNE","BK0239","BK4504","BK4585","LU2328871848.SGD","06160","688235","BK4535","BK4139","BK4505","LU0588546209.SGD","BK4526","BK1588"],"gpt_icon":0},{"id":"2483879852","title":"BeiGene to Rename as BeOne Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2483879852","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483879852?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:08","pubTimestamp":1731586083,"startTime":"0","endTime":"0","summary":"BeiGene  said Thursday it plans to change its name to BeOne Medicines, subject to shareholder approval.Once the name change is approved, the company's Nasdaq ticker will change to \"ONC.\"The name change is part of the company's global oncology growth strategy.Price: 222.99, Change: -4.06, Percent Change: -1.79","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4548","NQmain","BK4504","BGNE","BK4139","BK4535","BK4588","BK4585","BK4505","BK4526","MDCO","06160"],"gpt_icon":0},{"id":"2483772874","title":"BeiGene Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2483772874","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483772874?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:49","pubTimestamp":1731584999,"startTime":"0","endTime":"0","summary":"NasdaqGS:BGNE Earnings and Revenue Growth November 14th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 1.8%. Earnings per share  missed analyst estimates by 16%.Looking ahead, revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.The company's shares are down 3.6% from a week ago.Before we wrap up, we've discovered 2 warning signs for BeiGene that you should be aware of.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-third-quarter-2024-earnings-114959148.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BGNE"],"gpt_icon":0},{"id":"2483277608","title":"BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2483277608","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483277608?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:00","pubTimestamp":1731582000,"startTime":"0","endTime":"0","summary":"New name reflects Company’s bold vision to eradicate cancer by harnessing the transformative power of global collaboration and multisectoral partnerships. SAN MATEO, Calif. & BASEL, Switzerland, November 14, 2024----BeiGene, Ltd. , a global oncology company, today announced its intent to change the Company’s name to BeOne Medicines Ltd., confirming its commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible.\"One\" emphasizes our unity as a team and focus on bringing together patients, caregivers, scientists, healthcare providers, governments and industry with a shared mission to eliminate cancer together;The word \"Onc\" spelled in red within \"One\" illustrates our redoubled commitment to oncology; and. The new name is part of a broader strategic growth plan that has enabled the Company’s global oncology leadership since its inception in 2010. The Company recently reported $1 billion in quarterly total rev","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FDhVlbOJ_McE10SGfiL.UA--~B/aD00OTg7dz0yMjA4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/9e89270957de3a884a2fea3638a51409","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FDhVlbOJ_McE10SGfiL.UA--~B/aD00OTg7dz0yMjA4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/9e89270957de3a884a2fea3638a51409"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-unveils-proposed-name-change-110000321.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4526","BK4585","BK4535","BK4588","BK4505","BK4139","BK4548","BK4504","BGNE","MDCO"],"gpt_icon":1},{"id":"2483381828","title":"BeiGene: Strong Buy Recommendation Driven by Impressive Sales Growth and Promising Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2483381828","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483381828?lang=en_us&edition=fundamental","pubTime":"2024-11-14 16:45","pubTimestamp":1731573934,"startTime":"0","endTime":"0","summary":"Analyst Jill Wu of CMB International Securities maintained a Buy rating on BeiGene (BGNE – Research Report), with a price target of $276.02. Jill W...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beigene-strong-buy-recommendation-driven-by-impressive-sales-growth-and-promising-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beigene-strong-buy-recommendation-driven-by-impressive-sales-growth-and-promising-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BGNE"],"gpt_icon":0},{"id":"2483846630","title":"BeiGene’s Strong Financial Performance and Growth Potential Justifies Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2483846630","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483846630?lang=en_us&edition=fundamental","pubTime":"2024-11-14 15:38","pubTimestamp":1731569896,"startTime":"0","endTime":"0","summary":"BeiGene (BGNE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 12. Analyst Andrew Berens from ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beigenes-strong-financial-performance-and-growth-potential-justifies-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beigenes-strong-financial-performance-and-growth-potential-justifies-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BGNE"],"gpt_icon":0},{"id":"2483800209","title":"Beigene Ltd : Jefferies Raises Target Price to $286 From $284","url":"https://stock-news.laohu8.com/highlight/detail?id=2483800209","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483800209?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:05","pubTimestamp":1731503132,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nFWN3MK1KR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","BK4504","BGNE","BK4585","BK4588","688235","BK4548","BK0239","BK4526","BK4535"],"gpt_icon":0},{"id":"2483044965","title":"BeiGene’s Financial and Market Challenges: Navigating Risks in Drug Acceptance, Competition, and Geopolitical Tensions","url":"https://stock-news.laohu8.com/highlight/detail?id=2483044965","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483044965?lang=en_us&edition=fundamental","pubTime":"2024-11-13 14:01","pubTimestamp":1731477688,"startTime":"0","endTime":"0","summary":"BeiGene, Ltd. (BGNE) has disclosed a new risk, in the Share Price & Shareholder Rights category. BeiGene, Ltd. faces a multitude of business risks ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beigenes-financial-and-market-challenges-navigating-risks-in-drug-acceptance-competition-and-geopolitical-tensions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beigenes-financial-and-market-challenges-navigating-risks-in-drug-acceptance-competition-and-geopolitical-tensions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BGNE","BK4585","BK4526","BK4588","BK4548","BK4504","BK4535","BK4505"],"gpt_icon":0},{"id":"2483123046","title":"Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight","url":"https://stock-news.laohu8.com/highlight/detail?id=2483123046","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483123046?lang=en_us&edition=fundamental","pubTime":"2024-11-13 13:12","pubTimestamp":1731474732,"startTime":"0","endTime":"0","summary":"BeiGene Ltd  showcases robust revenue growth with a significant increase in product revenue.Research and development expenses reflect the company's commitment to innovation and pipeline expansion.Despite increased revenues, BeiGene Ltd  faces operational losses and challenges in net income.The company's strategic focus on oncology therapeutics and global clinical trials positions it for potential market leadership.GuruFocus has detected 4 Warning Signs with BGNE.BeiGene Ltd , a biotechnology firm specializing in oncology therapeutics, has released its 10-Q filing on November 12, 2024. The financial overview reveals a company experiencing substantial growth in product revenue, which climbed from $595,290 in the third quarter of 2023 to $993,447 in the same period of 2024. Collaboration revenue, however, has seen a decline, dropping from $186,018 to $8,152 year-over-year. Despite the increase in total revenues, which rose from $781,308 to $1.00 million, BeiGene Ltd  reported a net loss o","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vAjNqCZU2JM3EBPhpDWSbA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/77d185bde0304b047c89f166d6232969","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vAjNqCZU2JM3EBPhpDWSbA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/77d185bde0304b047c89f166d6232969"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/decoding-beigene-ltd-bgne-strategic-051212204.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","INAQU","TQQQ","BK4588","BK4139","BK4505",".IXIC","QLD","SQQQ","BK4526","BK4504","MNQmain","PSQ","BK4535","NQmain","QID","BGNE","BK4548"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.beigene.cn","stockEarnings":[{"period":"1week","weight":0.0068},{"period":"1month","weight":-0.138},{"period":"3month","weight":-0.0171},{"period":"6month","weight":0.2475},{"period":"1year","weight":0.0422},{"period":"ytd","weight":0.0563}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.062331},{"month":2,"riseRate":0.625,"avgChangeRate":0.017001},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.028933},{"month":4,"riseRate":0.444444,"avgChangeRate":0.028699},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.01513},{"month":6,"riseRate":0.555556,"avgChangeRate":0.015441},{"month":7,"riseRate":0.777778,"avgChangeRate":0.136456},{"month":8,"riseRate":0.555556,"avgChangeRate":0.036185},{"month":9,"riseRate":0.555556,"avgChangeRate":0.064683},{"month":10,"riseRate":0.555556,"avgChangeRate":0.004837},{"month":11,"riseRate":0.444444,"avgChangeRate":0.046584},{"month":12,"riseRate":0.375,"avgChangeRate":-0.023463}],"exchange":"NASDAQ","name":"BeiGene","nameEN":"BeiGene"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BeiGene(BGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BeiGene(BGNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BeiGene,BGNE,BeiGene股票,BeiGene股票老虎,BeiGene股票老虎国际,BeiGene行情,BeiGene股票行情,BeiGene股价,BeiGene股市,BeiGene股票价格,BeiGene股票交易,BeiGene股票购买,BeiGene股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BeiGene(BGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BeiGene(BGNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction